1
|
A new paradigm in public health assessment: Water fingerprinting for protein markers of public health using mass spectrometry. Trends Analyt Chem 2019. [DOI: 10.1016/j.trac.2019.115621] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
2
|
Jia S, Zhang R, Li Z, Li J. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget 2017; 8:55632-55645. [PMID: 28903450 PMCID: PMC5589689 DOI: 10.18632/oncotarget.17184] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 03/28/2017] [Indexed: 12/19/2022] Open
Abstract
Colorectal cancer (CRC) has been the fourth leading cause of cancer-related mortality worldwide. Owing to clonal evolution and selection, CRC treatment needs multimodal therapeutic approaches and due monitoring of tumor progression and therapeutic efficacy. Liquid biopsy, involving the use of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, may offer a promising noninvasive alternative for diagnosis and for real-time monitoring of tumor evolution and therapeutic response compared to traditional tissue biopsy. Monitoring of the disease processes can enable clinicians to readily adopt a strategy based on optimal therapeutic decision-making. This article provides an overview of the significant advances and the current clinical and biological significance of CTCs, ctDNA, and exosomes in CRC, as well as a comparison of the main merits and demerits of these three components. The hurdles that need to be resolved and potential directions to be followed with respect to liquid biopsies for detection and therapy of CRC are also discussed.
Collapse
Affiliation(s)
- Shiyu Jia
- Peking University Fifth School of Clinical Medicine, Beijing, People's Republic of China.,National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.,Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, People's Republic of China
| | - Rui Zhang
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.,Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, People's Republic of China
| | - Ziyang Li
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.,Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, People's Republic of China.,Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Jinming Li
- Peking University Fifth School of Clinical Medicine, Beijing, People's Republic of China.,National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.,Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, People's Republic of China
| |
Collapse
|
3
|
Piliarik M, Bocková M, Homola J. Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma. Biosens Bioelectron 2011; 26:1656-61. [PMID: 20864329 DOI: 10.1016/j.bios.2010.08.063] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Revised: 08/02/2010] [Accepted: 08/20/2010] [Indexed: 11/29/2022]
Abstract
Surface plasmon resonance (SPR) biosensor for high-throughput screening of protein biomarkers in diluted blood plasma is reported. The biosensor combines a high-resolution SPR imaging sensor and a high-density protein array with low-fouling background. The SPR imaging sensor utilizes polarization contrast and advanced referencing and provides a total of 120 sensing areas (each 200 μm×150 μm). Antibodies are immobilized on the sensing areas via hybridization of antibody-oligonucleotide conjugates to thiolated complementary oligonucleotides microspotted on the sensor surface (DNA-directed immobilization). A low-fouling background is achieved by covalent immobilization of bovine serum albumin to carboxyl-terminated thiols filling the areas among the thiolated oligonucleotides and outside the sensing areas. The biosensor was evaluated for detection of protein biomarkers relevant to cancer diagnostics--human chorionic gonadotropin (hCG) and activated leukocyte cell adhesion molecule (ALCAM) both in buffer and in 10% blood plasma. Limits of detection as low as 45 ng/mL (ALCAM) and 100 ng/mL (hCG) were achieved in blood plasma samples.
Collapse
Affiliation(s)
- Marek Piliarik
- Institute of Photonics and Electronics AS CR v.v.i., Chaberská 57, CZ-18251 Prague 8, Czech Republic
| | | | | |
Collapse
|
4
|
Van QN, Veenstra TD, Issaq HJ. Metabolic Profiling for the Detection of Bladder Cancer. Curr Urol Rep 2010; 12:34-40. [DOI: 10.1007/s11934-010-0151-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
5
|
Molecular detection of colorectal neoplasia. Gastroenterology 2010; 138:2127-39. [PMID: 20420950 DOI: 10.1053/j.gastro.2010.01.055] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2009] [Revised: 01/12/2010] [Accepted: 01/20/2010] [Indexed: 02/06/2023]
Abstract
A variety of noninvasive molecular approaches to colorectal cancer screening are emerging with potential to improve screening effectiveness and user-friendliness. These approaches are based on the sensitive assay of molecular markers in stool, blood, and urine samples. New methods, especially next generation stool-based tests, have been shown to detect both colorectal cancers and precancerous lesions with high accuracy. Validation of these technologies in average-risk populations are needed to establish their role for general colorectal cancer screening. This review addresses the biological rationale, technical advances, recent clinical performance data, and remaining issues with molecular screening for colorectal cancer.
Collapse
|
6
|
Zhou Y, Zhang X, Hua Y, Zhao Q, Wang X, Fan D. Monoclonal antibodies MC3 and MC5 can be used as a tool for screening colorectal cancer. Hybridoma (Larchmt) 2010; 29:179-81. [PMID: 20443712 DOI: 10.1089/hyb.2009.0081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
MC3 and MC5 are both colorectal cancer-specific MAbs previously prepared in our laboratory that can detect colorectal cancer with high sensitivity and specificity. Thus far the distribution of MC3-Ag and MC5-Ag in colorectal cancer remains largely unknown. In the present study, we have firstly found that the expression of MC3-Ag and MC5-Ag was higher in moderate-differentiated and poor-differentiated colorectal cancer tissue than that in well-differentiated colorectal cancer tissue by immunohistochemistry. The expression of MC5-Ag in colorectal cancer tissue without metastasis was found to be significantly less than that in tissue accompanied with metastasis. However, the expression of MC3-Ag in colorectal cancer tissue without metastasis was found similar to that in tissue accompanied with metastasis. The results showed that MC3-Ag and MC5-Ag might play important roles in colorectal carcinogenesis and that MC3 and MC5 could be used as a tool for screening colorectal cancer.
Collapse
Affiliation(s)
- Yi Zhou
- Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
| | | | | | | | | | | |
Collapse
|